Skip to main content
Caplight Logo









Mironid

Mironid

Private
GlasgowHealthcare & Life Scienceshttps://mironid.com/

Last Round

Series B

Aug 5, 2026

Total Funding Raised

$90.55M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Mironid is a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall molecule therapeuticsADPKDAutosomal Dominant Polycystic Kidney DiseasePDE4 enzymesbiopharmarare disease drugkidney disease treatmentpreclinical developmenttherapeutic pipelinebiotech startupcAMP signalingdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mironid Comparables

Compare Mironid with similar companies based on industry and business-model similarity.

Mironid comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Renasant Bio
80%
Novartis
76%
xCystence Bio
76%

Mironid Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 5, 2026
Series A ExtensionSep 13, 2023
Series AJun 20, 2016

Mironid Investors

Notable investors and investment history

Mironid investors
InvestorRounds
Roche Venture FundSeries B, Series A Extension, Series A
Epidarex CapitalSeries B, Series A Extension, Series A
European Investment FundSeries A Extension, Series A
Scottish National Investment BankSeries B
Sofinnova PartnersSeries B, Series A Extension, Series A
University of StrathclydeSeries B, Series A Extension, Series A
BioGeneration VenturesSeries B, Series A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 5, 2026

    $46M round with participation from BioGeneration Ventures and Epidarex Capital.

  • Jun 19, 2026

    Monthly visitors increased 58% MoM.

Mironid Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mironid Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mironid's valuation, stock price, and market status.

Firmographic Details

HeadquartersGlasgow
Employee Range16
Year Founded2015
Last FundingAug 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?